Megacap stocks are behemoths that set the tone for their industries, and their massive scale typically leads to wide moats. However, the downside is that most have already exploited their existing market opportunities and must invest heavily to expand further, a risky proposition.

These trade-offs can cause headaches for even the most seasoned professionals, which is why we started StockStory - to help you find high-quality companies that can grow their earnings no matter what. Keeping that in mind, here are two industry titans whose competitive advantages create flywheel effects and one whose existing offerings may be tapped out.

One Mega-Cap Stock to Sell:

GE Vernova (GEV)

Market Cap: $224.3 billion

Born from the energy business of industrial giant General Electric in a 2023 spin-off, GE Vernova (NYSE: GEV) designs, manufactures, and services power generation equipment and grid technologies to help customers build more reliable and sustainable electric systems.

Why Does GEV Fall Short?

1. Scale is a double-edged sword because it limits the company’s growth potential compared to its smaller competitors, as reflected in its below-average annual revenue increases of 3.6% for the last four years
2. Gross margin of 16.2% reflects its high production costs
3. Persistent operating margin losses suggest the business manages its expenses poorly

GE Vernova is trading at $831.75 per share, or 60.2x forward P/E. If you’re considering GEV for your portfolio, see our FREE research report to learn more.

Two Mega-Cap Stocks to Watch:

Broadcom (AVGO)

Market Cap: $1.59 trillion

Originally the semiconductor division of Hewlett Packard, Broadcom (NASDAQ: AVGO) is a semiconductor conglomerate spanning wireless communications, networking, and data storage as well as infrastructure software focused on mainframes and cybersecurity.

Why Will AVGO Outperform?

1. Annual revenue growth of 32.5% over the past two years was outstanding, reflecting market share gains this cycle
2. Offerings are difficult to replicate at scale and lead to a best-in-class gross margin of 76.5%
3. AVGO is a free cash flow machine with the flexibility to invest in growth initiatives or return capital to shareholders

Broadcom’s stock price of $336.24 implies a valuation ratio of 25.6x forward P/E. Is now a good time to buy? See for yourself in our in-depth research report, it’s free.

Amgen (AMGN)

Market Cap: $198.3 billion

Founded in 1980 during the early days of the biotechnology revolution, Amgen (NASDAQ: AMGN) is a biotechnology company that discovers, develops, and manufactures innovative medicines to treat serious illnesses like cancer, osteoporosis, and autoimmune diseases.

Why Does AMGN Stand Out?

1. Annual revenue growth of 14.2% over the last two years beat the sector average and underscores the unique value of its offerings
2. Revenue base of $36.75 billion gives it economies of scale and some negotiating power
3. Strong free cash flow margin of 28.6% enables it to reinvest or return capital consistently

At $368.37 per share, Amgen trades at 16.8x forward P/E. Is now the right time to buy? Find out in our full research report, it’s free.

Stocks We Like Even More

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it's flagging for this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.